Study to Evaluate Multiple Ascending Dose and Multi-Dose of DT-216 in Adult Patients With Friedreich Ataxia

Inclusion Criteria: * Genetically confirmed diagnosis of Friedreich Ataxia with homozygous GAA repeat expansions. * Able and willing to sign informed consent form prior to study enrollment. * Stage 5.5 or less on the Functional Staging for Ataxia (FSA) at screening. Exclusion Criteria: * Has any concomitant medical condition that in the opinion of the investigator, puts the participant at risk or precludes participant from completing the study. * Has clinically significant abnormal laboratory results. * Has significant cardiac disease. * Received an investigational drug within 3 months of screening.